RUNX2 and neoplasm: In a tissue microarray study of 87 primary urothelial carcinoma and 17 control cases, we found that RUNX2 independently predicted early tumour recurrence in patients with bladder urothelial carcinoma (Abdelzaher and Kotb, 2016).